ArticleJournal of bone and mineral metabolism2026
Facial skin aging is a potential osteoporosis-associated marker: evidence from both observational and genetic studies.
Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionFacial skin aging (FSA) is a very easily observable indicator of aging, but whether FSA is associated with osteoporosis is still unknown. MATERIALS AND
methodsBased on the individual-level datasets from UK Biobank, this study calculated the PhenoAge (an accurate aging parameter), genetic risk score (GRS) and PhenoAge_advance, and performed multiple linear correlation analyses and Cox regression analyses. Based on the summary data from genome-wide association Studies (GWAS), linkage disequilibrium regression (LDSC), pleiotropic analysis under composite null hypothesis (PLACO) and Mendelian randomization (MR) analysis were performed to reveal shared genetic components and infer causal effects, respectively.
resultsHigher degrees of FSA were associated with lower eBMD (p < 0.001), and FSA was positively associated with the risks of osteoporosis (HR = 1.852, p < 0.001) and fracture (HR = 1.501, p < 0.001). However, FSA was not genetically associated as well as causally associated with all studied osteoporosis-related traits. In addition, we found significant phenotypic and genetic correlations between FSA and PhenoAge (rp = -0.137, p < 0.05) as well as between PhenoAge and fractures (rg = 0.092, p < 0.05).
conclusionFSA, PhenoAge and osteoporosis are three aging-related parameters that coexist with aging, and the aging process is accompanied by FSA and osteoporosis. FSA may serve as a marker for the onset of osteoporosis. These findings provide clues for early detection of bone loss in at-risk populations and for OP diagnosis using accurate clinical tools.
Indexed as
Identifiers
41193836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.